Funds
Newton Biocapital II
NBC II is currently building a diverse and balanced portfolio with currently :
- 3 European and 1 Japanese company
- Company stage ranging from research to preclinical and clinical (at first investment)
- Investments in a variety of disease areas and technologies
The growth of our portfolio companies contributed to a substantial regional increase in regional employment, in line with our strategy for impact.
Want to know more? Contact us!
Have a great business idea already? Submit your proposal to become a part of our portfolio!
Our Sustainability risk Policy
Newton Biocapital is committed to building a Sustainable portfolio compliant with the SFDR Sustainability risk requirements by introducing a selection of Environmental, Social and Corporate Governance principles, which form an inherent part of our investment decisions. Our Sustainability risk policy is aligned with our mission of value creation for all.
Newton Biocapital I
Diverse and balanced portfolio of 14 companies with:
- 10 European and 4 Japanese companies
- Company stage ranging from research to preclinical and clinical (at first investment)
- Investments in a variety of disease areas and technologies
The growth of our portfolio companies contributed to a substantial regional increase in regional employment, in line with our strategy for impact.
About
We attracted investments from other funds and built strong international investor syndicates.
The growth of our portfolio companies contributed to a substantial regional increase in regional employment, in line with our strategy for impact
NBC I: Sustainability-related Disclosures
Although it was conducted with the same guiding principles, NBC I was established before we implemented our full Sustainability risk Policy.